Pleurodynia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image

New

Pleurodynia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Report
183 Pages
March 2025
Region: Global
TechSci Research
ID: 5908198

The Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024, and is expected to reach USD 195.59 Million by 2030, rising at a CAGR of 5.25%. The Global Pleurodynia Treatment Market represents a rapidly evolving segment within the healthcare industry, driven by advancements in diagnostic technology and increasing disease prevalence. Pleurodynia, commonly referred to as "Devil’s Grip," is a viral infection primarily caused by enteroviruses, notably Coxsackievirus, and is characterized by acute chest pain and myalgia, predominantly affecting children and young adults.

Market growth is underpinned by significant developments in molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which have substantially improved diagnostic precision and reduced the time to detection. These innovations enhance early-stage identification and allow for timely intervention, ultimately improving patient outcomes.

However, the market faces considerable challenges, primarily due to the lack of targeted antiviral therapies and diagnostic complexities. The absence of specialized treatment options results in a reliance on symptomatic management, limiting the scope of therapeutic advancements. Furthermore, pleurodynia’s clinical presentation often mimics cardiac and respiratory disorders, leading to frequent misdiagnosis and delayed or inappropriate treatment. Despite these hurdles, the global pleurodynia treatment market is positioned for sustained growth, fueled by rising incidence rates and continued investment in diagnostic research. Addressing treatment gaps and refining diagnostic protocols will be critical to unlocking the market’s full potential and enhancing patient care.

Key Market Drivers

Advancements in Medical Research and Technology

In recent years, the healthcare industry has experienced an unprecedented surge in medical research and technological advancements. These innovations have played a pivotal role in driving the growth of the Global Pleurodynia Treatment Market. Cutting-edge diagnostic tools and therapeutic options have been developed, significantly enhancing the management of pleurodynia.

One notable advancement is the utilization of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) tests. These tests have revolutionized the accuracy and speed of pleurodynia diagnosis. By detecting the viral RNA in patient samples, PCR tests provide rapid and precise results, enabling healthcare professionals to initiate treatment promptly. NGS has also emerged as a game-changer in pleurodynia diagnosis and research. This high-throughput sequencing technology allows for the comprehensive analysis of viral genomes, aiding in the understanding of pleurodynia strains and their genetic variations. Such insights are invaluable for the development of targeted treatments.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges hindering the growth of the Global Pleurodynia Treatment Market is the limited awareness among the general population. Pleurodynia, often referred to as "Devil's Grip," is a relatively uncommon viral infection. Many individuals may not recognize its symptoms, which can mimic other, more common ailments. This lack of awareness results in delayed diagnosis and treatment, impacting market growth.

The symptoms of pleurodynia, including severe chest pain and muscle aches, overlap with those of other respiratory and musculoskeletal conditions. Healthcare professionals may misdiagnose pleurodynia as conditions like pneumonia or muscular strain, leading to inappropriate treatment. Accurate and timely diagnosis is crucial for the effective management of pleurodynia, and misdiagnosis can slow down market expansion.

Key Market Trends

Advancements in Diagnostic Technologies

One significant trend in the Global Pleurodynia Treatment Market is the rapid advancement of diagnostic technologies. Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have gained prominence. These techniques enable healthcare professionals to detect pleurodynia with higher accuracy and speed by identifying viral RNA in patient samples. The adoption of these cutting-edge diagnostic tools is improving the efficiency of pleurodynia diagnosis and facilitating early treatment initiation.

Another notable trend is the development of point-of-care testing for pleurodynia. Point-of-care tests provide rapid results at the patient's bedside or in outpatient settings. These tests are particularly beneficial in regions with limited access to advanced healthcare facilities. The availability of point-of-care tests is expected to enhance the early detection and management of pleurodynia.

Key Market Players

Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Sanofi SA
Johnson & Johnson
Merck & Co Inc.
GlaxoSmithKline PLC
Reckitt Benckiser PLC
Bayer AG
Novartis AG

Report Scope:

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pleurodynia Treatment Market, By Diagnosis:

Blood test
Culture test
X-ray

Pleurodynia Treatment Market, By Treatment:

Analgesics or Painkillers
Immunoglobulin

Pleurodynia Treatment Market, By Mode of Administration:

Oral
Injections or infusion

Pleurodynia Treatment Market, By End-User:

Hospitals
Pharmacy
Others

Pleurodynia Treatment Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pleurodynia Treatment Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnosis (Blood test, Culture test, X-ray)
5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin)
5.2.3. By Mode of Administration (Oral, Injections or infusion)
5.2.4. By End-User (Hospitals, Pharmacy, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map

6. North America Pleurodynia Treatment Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnosis
6.2.2. By Treatment
6.2.3. By Mode of Administration
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Pleurodynia Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnosis
6.3.1.2.2. By Treatment
6.3.1.2.3. By Mode of Administration
6.3.1.2.4. By End User
6.3.2. Canada Pleurodynia Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnosis
6.3.2.2.2. By Treatment
6.3.2.2.3. By Mode of Administration
6.3.2.2.4. By End User
6.3.3. Mexico Pleurodynia Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnosis
6.3.3.2.2. By Treatment
6.3.3.2.3. By Mode of Administration
6.3.3.2.4. By End User

7. Europe Pleurodynia Treatment Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnosis
7.2.2. By Treatment
7.2.3. By Mode of Administration
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pleurodynia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnosis
7.3.1.2.2. By Treatment
7.3.1.2.3. By Mode of Administration
7.3.1.2.4. By End User
7.3.2. United Kingdom Pleurodynia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnosis
7.3.2.2.2. By Treatment
7.3.2.2.3. By Mode of Administration
7.3.2.2.4. By End User
7.3.3. Italy Pleurodynia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnosis
7.3.3.2.2. By Treatment
7.3.3.2.3. By Mode of Administration
7.3.3.2.4. By End User
7.3.4. France Pleurodynia Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnosis
7.3.4.2.2. By Treatment
7.3.4.2.3. By Mode of Administration
7.3.4.2.4. By End User
7.3.5. Spain Pleurodynia Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnosis
7.3.5.2.2. By Treatment
7.3.5.2.3. By Mode of Administration
7.3.5.2.4. By End User

8. Asia-Pacific Pleurodynia Treatment Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnosis
8.2.2. By Treatment
8.2.3. By Mode of Administration
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pleurodynia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnosis
8.3.1.2.2. By Treatment
8.3.1.2.3. By Mode of Administration
8.3.1.2.4. By End User
8.3.2. India Pleurodynia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnosis
8.3.2.2.2. By Treatment
8.3.2.2.3. By Mode of Administration
8.3.2.2.4. By End User
8.3.3. Japan Pleurodynia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnosis
8.3.3.2.2. By Treatment
8.3.3.2.3. By Mode of Administration
8.3.3.2.4. By End User
8.3.4. South Korea Pleurodynia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Diagnosis
8.3.4.2.2. By Treatment
8.3.4.2.3. By Mode of Administration
8.3.4.2.4. By End User
8.3.5. Australia Pleurodynia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Diagnosis
8.3.5.2.2. By Treatment
8.3.5.2.3. By Mode of Administration
8.3.5.2.4. By End User

9. South America Pleurodynia Treatment Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnosis
9.2.2. By Treatment
9.2.3. By Mode of Administration
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pleurodynia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnosis
9.3.1.2.2. By Treatment
9.3.1.2.3. By Mode of Administration
9.3.1.2.4. By End User
9.3.2. Argentina Pleurodynia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnosis
9.3.2.2.2. By Treatment
9.3.2.2.3. By Mode of Administration
9.3.2.2.4. By End User
9.3.3. Colombia Pleurodynia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnosis
9.3.3.2.2. By Treatment
9.3.3.2.3. By Mode of Administration
9.3.3.2.4. By End User

10. Middle East and Africa Pleurodynia Treatment Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnosis
10.2.2. By Treatment
10.2.3. By Mode of Administration
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pleurodynia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnosis
10.3.1.2.2. By Treatment
10.3.1.2.3. By Mode of Administration
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Pleurodynia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnosis
10.3.2.2.2. By Treatment
10.3.2.2.3. By Mode of Administration
10.3.2.2.4. By End User
10.3.3. UAE Pleurodynia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnosis
10.3.3.2.2. By Treatment
10.3.3.2.3. By Mode of Administration
10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Pleurodynia Treatment Market: SWOT Analysis

14. Competitive Landscape

14.1. Bristol-Myers Squibb Co
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. F. Hoffmann-La Roche Ltd
14.3. Pfizer Inc
14.4. Sanofi SA
14.5. Johnson & Johnson
14.6. Merck & Co Inc.
14.7. GlaxoSmithKline PLC
14.8. Reckitt Benckiser PLC
14.9. Bayer AG
14.10. Novartis AG

15. Strategic Recommendations

Companies Mentioned

Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Sanofi SA
Johnson & Johnson
Merck & Co Inc.
GlaxoSmithKline PLC
Reckitt Benckiser PLC
Bayer AG
Novartis AG

Table Information

Report Attribute	Details
No. of Pages	183
Published	March 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 143.55 Million
Forecasted Market Value ( USD ) by 2030	$ 195.59 Million
Compound Annual Growth Rate	5.2%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4107EUR$4,500USD£3,502GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5019EUR$5,500USD£4,280GBP